title: Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. hardyta@lilly.com
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Hardy
authors.forename: Adam L
authors.initials: AL
authors.lastname: Meyers
authors.forename: Jun
authors.initials: J
authors.lastname: Yu
authors.forename: Sudha S
authors.initials: SS
authors.lastname: Shankar
authors.forename: Helmut O
authors.initials: HO
authors.lastname: Steinberg
authors.forename: Niels K
authors.initials: NK
authors.lastname: Porksen
mesh_terms: D001569:Benzodiazepines / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002096:C-Peptide / Q000097:blood*; D015309:Glucose Clamp Technique; D006801:Humans; D006943:Hyperglycemia / Q000097:blood; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism*; D000077152:Olanzapine; D012016:Reference Values; D018967:Risperidone / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*
chemical_list: D001569:Benzodiazepines; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D000077152:Olanzapine; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors